German pharmaceutical firm BioNTech says its earnings grew once more within the third quarter
BERLIN — German pharmaceutical firm BioNTech, which partnered with Pfizer to develop the primary extensively used COVID-19 vaccine, stated Tuesday that its earnings grew once more within the third quarter.
BioNTech, which is predicated in Mainz, reported a web revenue of greater than 3.2 billion euros ($3.7 billion) for the July-September interval. That compares with the corporate’s lack of 210 million euros ($243 million) in the identical interval a yr earlier and a second-quarter revenue of virtually 2.8 billion euros ($3.2 billion). Vaccinations with the Pfizer-BioNTech vaccine began began in December.
BioNTech reported income of almost 6.1 billion euros ($7.1 billion), up from 67.5 million euros ($78 million) within the third quarter of 2020. It stated that greater than 2 billion doses of the COVID-19 vaccine, marketed as Comirnaty, had been delivered this yr as of Nov. 2.
The corporate has stated the windfall from its mRNA-based coronavirus vaccine will assist it to develop medicine towards most cancers and different illnesses.
BioNTech’s web revenue for the yr’s first 9 months was over 7.1 billion euros ($8.2 billion), in contrast with a lack of 351.7 million euros ($407 million) in the identical interval a yr earlier.
———
Observe AP’s pandemic protection at https://apnews.com/hub/coronavirus-pandemic